Gecko crude peptides inhibit migration and lymphangiogenesis by down regulating the expression of VEGF-C in human hepatocellular carcinoma cells and human lymphatic endothelial cells
2017-01-16MengliGUOCaiWANGYimengDUANJiangangWANG
Meng-li GUO,Cai-e WANG,Yi-meng DUAN,Jian-gang WANG
(1.Medical College,Henan University of Science and Technology,Luoyang 471023,Henan Province,China;2.The First Affiliated Hospital,and College of Clinical Medicine of Henan University of Science and Technology,Luoyang 471003,China)
T1-12
Gecko crude peptides inhibit migration and lymphangiogenesis by down regulating the expression of VEGF-C in human hepatocellular carcinoma cells and human lymphatic endothelial cells
Meng-li GUO1,Cai-e WANG2,Yi-meng DUAN1,Jian-gang WANG1
(1.Medical College,Henan University of Science and Technology,Luoyang 471023,Henan Province,China;2.The First Affiliated Hospital,and College of Clinical Medicine of Henan University of Science and Technology,Luoyang 471003,China)
OBJECTIVETo explore the role of gecko crude peptides(GCPs)in the proliferation,apoptosis,migration and lymphangiogenesis of human hepatocellular carcinoma cells(HepG2)and human lymphaticendothelial cells(HLECs)in vitro.METHODSThe 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT)assay was used to evaluate the anti-proliferative effect of GCPs and siRNA-VEGF-C on HepG2 cells,Hoechst 33258 staining and flow cytometry were performed to analyze cycle and apoptosis.The migration and invasion ability of cells were assayed by transwell chamber experiment and wound-healing assay.The protein and mRNA expressions of vascular endo⁃thelial growth factor-C(VEGF-C)and CXC chemokine receptor-4(CXCR4)were detected by q-PCR,immunofluorescence,Western blot.The protein expressions of the extracellular signal regulated kinase(ERKI/2),c-Jun N-terminal kinase(JNK),p38-mitogen activated protein kinases(p38 MAPK),serine/threonine kinase(Akt)and phosphatidylinositol-3-kinase(PI3K)were detected by western blot.The anti-lymphangiogenesis effect of GCPs on the HLECs was analyzed using an in vitro tube-formation assay.The protein and mRNA expressions of vascular endothelial growth factor receptor-3(VEGFR-3)and stromal cell-derived factor-1(SDF-1)were detected by q-PCR,Western blot.RESULTSGCPs and siRNA-VEGF-C inhibited HepG2 proliferation,invasion and migration,and the most obvious inhibitory effect was both synergistic effects.Thus,GCPs suppressed HLECs proliferation,migration and tubelike structure formationin a dose-dependent manner,and had inhibitory effect of tumor-induced lymphangiogenesis in vitro.Additionally,we found that GCPs and siRNA-VEGF-C decreased the expressions of MMP-2,MMP-9,VEGF-C,CXCR4,phospho-ERK1/2,phospho-P38,phospho-JNK and PI3K in HepG2 cells.Moreover,GCPs had a dose-dependent depressive effecton the expressions of VEGFR-3,SDF-1 in HLECs.CONCLUSIONThe low expression of VEGF-C mediated by siRNAVEGF-C and GCPs inhibit tumor proliferation,invasion and migrationby suppressing the MAPK signaling pathway through reduced levels of VEGF-C,and GCPs inhibit tumor lymphangiogenesis by suppressing the CXCR4/SDF-1 signaling pathway through suppressed VEGF-C/VEGFR-3.
gecko crude peptides;hepatic carcinoma;vascular endothelial growth factor-C;RNA interference(RNAi);lymphangiogenesis
The project supported by Medical Science and Technology Research Project of Henan Province(142102310031)
Jian-gang WANG,Tel:13838819637,E-mail:ylwjg@163.com
杂志排行
中国药理学与毒理学杂志的其它文章
- Identification and optimization of a potent and highly selective D3 dopamine receptor agonist
- Protective role of FoxO transcription factors against oxidative stress-induced chondrocyte dysfunction:a new therapeutic target for osteoarthritis
- Meta-analysis of serum copper and heart failure
- Involvement of cysteinyl leukotriene signaling in microglial morphological changes and CASP1 expression in vitro
- Inhibitory effect of compound NS5806 on cardiac transient outward potassium channel dependents on interaction between auxiliary subunits
- Connexin 40-formed GJIC increases the phototoxicity of photodynamic therapy through ROS-and calcium-mediated pathways
